左炔诺孕酮宫内缓释系统治疗子宫内膜异位症的效果及安全性评估  

Therapeutic effect and safety evaluation of levonorgestrel intrauterine sustained release system in the treatment of endometriosis

作　　者：张伟娜[1] ZHANG Weina(Department of Obstetrics and Gynecology, Jiamusi Central Hospital in Heilongjiang Province, Jiamusi 154002, China)

机构地区：[1]黑龙江省佳木斯市中心医院妇产科

出　　处：《中国现代医生》2019年第20期69-71,共3页China Modern Doctor

摘　　要：目的分析左炔诺孕酮宫内缓释系统对子宫内膜异位症治疗的临床疗效与安全性。方法选择我院2016年5月~2017年4月所收治的66例子宫内膜异位症患者作为本次研究的对象,采取随机数字表法将66例患者分为对照组和实验组,各33例,对照组采取口服米非司酮进行治疗,实验组则采取左炔诺孕酮宫内缓释系统进行治疗,分析对比两组患者各项指标的变化情况以及不良反应发生率等。结果经过治疗,实验组患者有效率(96.97%)优于对照组(75.76%),差异具有统计学意义(P<0.05)。且治疗后,实验组血清TIMP-1(134.5±36.2)、MMP-9(132.6±42.2),MMP-9/TIMP-1(1.07±0.25)显著低于对照组。两组不良反应无明显差异(P>0.05)。结论左炔诺孕酮宫内缓释系统对于子宫内膜异位症患者的治疗效果更加有效,能够对患者的子宫内膜厚度、血清学相关指标、激素水平大幅度改善,无明显的不良反应,且安全性高,值得在临床中广泛推广应用。Objective To analyze the clinical efficacy and safety of levonorgestrel intrauterine sustained release system in the treatment of endometriosis. Methods 66 patients with endometriosis admitted in our hospital from May 2016 to April 2017 were selected as subjects of this study. The 66 patients were divided into control group and experiment by random number table method, with 33 cases in each group. The control group was treated with oral mifepristone. The experimental group was treated with levonorgestrel intrauterine sustained-release system. The changes of the indicators and adverse reaction rate in the two groups of patients with ectopic diseases were compared. Results After clinical treatment, the effective rate of the experimental group was 96.97%, which was better than that of the control group(75.76%, P<0.05), The difference was statistically significant. After treatment, serum TIMP-1(134.5 ±36.2), MMP-9(132.6±42.2), and MMP-9/TIMP-1(1.07 ±0.25) in the experimental group were significantly lower than those in the control group. There was no significant difference in adverse reactions between the two groups(P>0.05). Conclusion The levonorgestrel intrauterine sustained release system is more effective in the treatment of patients with endometriosis, which can greatly improve the endometrial thickness, serum related indicators and hormone levels of patients, without obvious defects. It has high safety and is worthy of widespread application in the clinic.

关 键 词：左炔诺孕酮宫内缓释系统 米非司酮 子宫内膜异位症 不良反应 

分 类 号：R711.7[医药卫生—妇产科学]